JP2009518410A - インフルエンザウイルスワクチンアジュバントまたは免疫‐刺激因子としてのｄｓＲＮＡ - Google Patents
インフルエンザウイルスワクチンアジュバントまたは免疫‐刺激因子としてのｄｓＲＮＡ Download PDFInfo
- Publication number
- JP2009518410A JP2009518410A JP2008544428A JP2008544428A JP2009518410A JP 2009518410 A JP2009518410 A JP 2009518410A JP 2008544428 A JP2008544428 A JP 2008544428A JP 2008544428 A JP2008544428 A JP 2008544428A JP 2009518410 A JP2009518410 A JP 2009518410A
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- dsrna
- avian influenza
- immune
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 title claims abstract description 12
- 102000040650 (ribonucleotides)n+m Human genes 0.000 title claims abstract description 12
- 229940124873 Influenza virus vaccine Drugs 0.000 title description 2
- 239000012646 vaccine adjuvant Substances 0.000 title description 2
- 229960005486 vaccine Drugs 0.000 claims abstract description 36
- 239000002671 adjuvant Substances 0.000 claims abstract description 17
- 229960003971 influenza vaccine Drugs 0.000 claims abstract description 16
- 230000001154 acute effect Effects 0.000 claims abstract description 11
- 230000001684 chronic effect Effects 0.000 claims abstract description 11
- 208000036142 Viral infection Diseases 0.000 claims abstract description 9
- 230000009385 viral infection Effects 0.000 claims abstract description 9
- 206010064097 avian influenza Diseases 0.000 claims description 26
- 208000002979 Influenza in Birds Diseases 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 19
- 241000700605 Viruses Species 0.000 claims description 15
- 241000712461 unidentified influenza virus Species 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 14
- 230000001737 promoting effect Effects 0.000 claims description 8
- 230000001932 seasonal effect Effects 0.000 claims description 8
- 230000036039 immunity Effects 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 230000035772 mutation Effects 0.000 claims description 7
- 229960004854 viral vaccine Drugs 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 5
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 230000008707 rearrangement Effects 0.000 claims description 4
- 230000003902 lesion Effects 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 229960000172 trivalent influenza vaccine Drugs 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 210000004102 animal cell Anatomy 0.000 claims 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 210000002845 virion Anatomy 0.000 claims 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 10
- 210000002850 nasal mucosa Anatomy 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 229940031418 trivalent vaccine Drugs 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 102000007445 2',5'-Oligoadenylate Synthetase Human genes 0.000 description 1
- 108010086241 2',5'-Oligoadenylate Synthetase Proteins 0.000 description 1
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 1
- 108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74290605P | 2005-12-07 | 2005-12-07 | |
| US75289805P | 2005-12-23 | 2005-12-23 | |
| US79323906P | 2006-04-20 | 2006-04-20 | |
| PCT/US2006/046356 WO2007067517A2 (en) | 2005-12-07 | 2006-12-06 | Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013013055A Division JP2013075920A (ja) | 2005-12-07 | 2013-01-28 | インフルエンザウイルスワクチンアジュバントまたは免疫‐刺激因子としてのｄｓＲＮＡ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009518410A true JP2009518410A (ja) | 2009-05-07 |
| JP2009518410A5 JP2009518410A5 (enExample) | 2010-02-25 |
Family
ID=38123418
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008544428A Pending JP2009518410A (ja) | 2005-12-07 | 2006-12-06 | インフルエンザウイルスワクチンアジュバントまたは免疫‐刺激因子としてのｄｓＲＮＡ |
| JP2013013055A Pending JP2013075920A (ja) | 2005-12-07 | 2013-01-28 | インフルエンザウイルスワクチンアジュバントまたは免疫‐刺激因子としてのｄｓＲＮＡ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013013055A Pending JP2013075920A (ja) | 2005-12-07 | 2013-01-28 | インフルエンザウイルスワクチンアジュバントまたは免疫‐刺激因子としてのｄｓＲＮＡ |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US7943147B2 (enExample) |
| EP (1) | EP1957101A4 (enExample) |
| JP (2) | JP2009518410A (enExample) |
| AU (1) | AU2006322073A1 (enExample) |
| CA (1) | CA2632516C (enExample) |
| WO (1) | WO2007067517A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005009337A2 (en) * | 2003-05-16 | 2005-02-03 | Hemispherx Biopharma | Treating severe acute respiratory syndrome |
| US20060035859A1 (en) * | 2003-05-16 | 2006-02-16 | Hemispherx Biopharma | Treating severe and acute viral infections |
| JP2009518410A (ja) * | 2005-12-07 | 2009-05-07 | へミスフェリックス・バイオファーマ | インフルエンザウイルスワクチンアジュバントまたは免疫‐刺激因子としてのｄｓＲＮＡ |
| AU2008266910A1 (en) * | 2007-06-18 | 2008-12-24 | Hemispherx Biopharma, Inc. | Early intervention of viral infections with immune activators |
| EP2197497B1 (en) | 2007-09-27 | 2016-06-01 | ImmunoVaccine Technologies Inc. | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
| US20100310600A1 (en) * | 2008-02-15 | 2010-12-09 | Carter William A | Selective agonist of toll-like receptor 3 |
| EP2271361A1 (en) * | 2008-04-16 | 2011-01-12 | Université de Lausanne | Method and vaccine for optimizing the specific immune responses |
| JP5715051B2 (ja) * | 2008-06-05 | 2015-05-07 | イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． | リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物 |
| EP2413961B1 (en) * | 2009-03-31 | 2016-08-17 | Japan As Represented By The Director-General Of National Institute Of Infectious Diseases | Method for prophylaxis of influenza using vaccine for intranasal administration |
| US10105435B2 (en) | 2011-10-06 | 2018-10-23 | Immunovaccine Technologies Inc. | Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof |
| EP4023244A4 (en) * | 2019-08-28 | 2023-11-01 | NA Vaccine Institute | INFLUENZA VACCINE COMPOSITION BASED ON A NOVEL NUCLEIC ACID |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3906092A (en) * | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
| US4024222A (en) * | 1973-10-30 | 1977-05-17 | The Johns Hopkins University | Nucleic acid complexes |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4349538A (en) * | 1979-12-07 | 1982-09-14 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid |
| CA1326450C (en) * | 1985-08-26 | 1994-01-25 | William A. Carter | Modulation of aids virus-related events by double stranded rnas (dsrnas) |
| US5132292A (en) * | 1990-05-25 | 1992-07-21 | Hem Research, Inc. | Treatment of viral hepatitis |
| US6589529B1 (en) * | 1998-10-30 | 2003-07-08 | Children's Hospital Medical Center | Rotavirus subunit vaccine |
| GB0119346D0 (en) * | 2001-08-08 | 2001-10-03 | Bioclones Proprietary Ltd | Process for the maturation of dendritic cells |
| WO2005014038A1 (ja) | 2003-08-11 | 2005-02-17 | The Research Foundation For Microbial Diseases Of Osaka University | 粘膜免疫誘導アジュバントを含む新規ワクチン |
| US7834064B2 (en) * | 2005-01-03 | 2010-11-16 | Andres Mario Salazar | Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs |
| JP2009518410A (ja) * | 2005-12-07 | 2009-05-07 | へミスフェリックス・バイオファーマ | インフルエンザウイルスワクチンアジュバントまたは免疫‐刺激因子としてのｄｓＲＮＡ |
| CN101652062A (zh) | 2007-03-05 | 2010-02-17 | 犹他州立大学 | Toll样受体3(TLR3)的限制性激动剂 |
-
2006
- 2006-12-06 JP JP2008544428A patent/JP2009518410A/ja active Pending
- 2006-12-06 US US11/634,389 patent/US7943147B2/en active Active
- 2006-12-06 CA CA2632516A patent/CA2632516C/en active Active
- 2006-12-06 AU AU2006322073A patent/AU2006322073A1/en not_active Abandoned
- 2006-12-06 WO PCT/US2006/046356 patent/WO2007067517A2/en not_active Ceased
- 2006-12-06 EP EP06844824A patent/EP1957101A4/en not_active Withdrawn
-
2011
- 2011-04-19 US US13/064,824 patent/US20110223198A1/en not_active Abandoned
-
2013
- 2013-01-28 JP JP2013013055A patent/JP2013075920A/ja active Pending
-
2014
- 2014-11-11 US US14/537,981 patent/US20150064216A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3906092A (en) * | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
| US4024222A (en) * | 1973-10-30 | 1977-05-17 | The Johns Hopkins University | Nucleic acid complexes |
| US4130641A (en) * | 1973-10-30 | 1978-12-19 | Ts O Paul O P | Induction of interferon production by modified nucleic acid complexes |
Non-Patent Citations (6)
| Title |
|---|
| JPN6012008520; 一戸猛志 他: 臨床免疫 Ｖｏｌ．４３， Ｎｏ．６, 200506, ｐ．６４７-６５１ * |
| JPN6012008522; ＣＡＲＴＥＲ，Ｗ．Ａ． ｅｔ ａｌ: Ｉｎｔｅｒｎａｔｉｏｎａｌ ｊｏｕｒｎａｌ ｏｆ ｉｍｍｕｎｏｐｈａｒｍａｃｏｌｏｇｙ Ｖｏｌ．１３, 1991, ｐ．６９-７６ * |
| JPN6012008525; ＩＣＨＩＮＯＨＥ，Ｔ． ｅｔ ａｌ: Ｊｏｕｒｎａｌ ｏｆ ｖｉｒｏｌｏｇｙ Ｖｏｌ．７９， Ｎｏ．５, 200503, ｐ．２９１０-９ * |
| JPN6012008527; ＷＯＮＧ，Ｊ．Ｐ． ｅｔ ａｌ: Ａｎｔｉｍｉｃｒｏｂｉａｌ ａｇｅｎｔｓ ａｎｄ ｃｈｅｍｏｔｈｅｒａｐｙ Ｖｏｌ．３９， Ｎｏ．１１, 1995, ｐ．２５７４-６ * |
| JPN6012008529; ＳＡＲＡＶＯＬＡＣ，Ｅ．Ｇ． ｅｔ ａｌ: Ｖａｃｃｉｎｅ Ｖｏｌ．１９， Ｎｏ．１７-１９, 2001, ｐ．２２２７-３２ * |
| JPN6012008532; 板村繁之: 日本臨床 Ｖｏｌ．５８， Ｎｏ．１, 2000, ｐ．２５５-２６４ * |
Also Published As
| Publication number | Publication date |
|---|---|
| US7943147B2 (en) | 2011-05-17 |
| US20070224219A1 (en) | 2007-09-27 |
| CA2632516C (en) | 2018-05-15 |
| US20150064216A1 (en) | 2015-03-05 |
| US20110223198A1 (en) | 2011-09-15 |
| EP1957101A2 (en) | 2008-08-20 |
| WO2007067517A3 (en) | 2008-01-31 |
| WO2007067517A2 (en) | 2007-06-14 |
| CA2632516A1 (en) | 2007-06-14 |
| JP2013075920A (ja) | 2013-04-25 |
| EP1957101A4 (en) | 2010-04-07 |
| AU2006322073A1 (en) | 2007-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013075920A (ja) | インフルエンザウイルスワクチンアジュバントまたは免疫‐刺激因子としてのｄｓＲＮＡ | |
| AU646257B2 (en) | Oral vaccine comprising antigen surface-associated with red blood cells | |
| Hoffman et al. | N, N-dioctadecyl-N′, N′-bis (2-hydroxyethyl) propanediamine: antiviral activity and interferon stimulation in mice | |
| US20100104533A1 (en) | Early intervention of viral infection with immune activators | |
| JP2011057605A (ja) | 粘膜投与型ワクチン | |
| JP2009209086A (ja) | 粘膜投与型ワクチン | |
| Hoover et al. | N-dihydrogalactochitosan serves as an effective mucosal adjuvant for intranasal vaccine in combination with recombinant viral proteins against respiratory infection | |
| Couch | Measures for control of influenza | |
| CN101820904A (zh) | 引起针对大流行性流感病毒的免疫应答的方法 | |
| RU2437664C1 (ru) | Средство профилактики птичьего гриппа у млекопитающих | |
| AU2013206335B2 (en) | dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants | |
| CN106924282B (zh) | 聚醚酰亚胺在制备预防流感病毒感染的药物中的应用 | |
| US20230295582A1 (en) | Influenza virus backbone | |
| CN101410133A (zh) | 作为流感病毒疫苗佐剂或免疫刺激物的dsRNA | |
| CN101594881B (zh) | 吸附灭活流感疫苗及其制备方法 | |
| WO2012164928A1 (ja) | Ｈ５ｎ１型インフルエンザワクチン及び感染防御キット | |
| CN121127263A (zh) | 用于预防流感及冠状病毒感染症的混合疫苗 | |
| Duggal et al. | COVID-19 VACCINES; A COMPARATIVE ANALYSIS OF THEIR DISTINGUISHING CHARACTERISTICS EFFICACY, EFFECTIVENESS AND ADVERSE EFFECTS | |
| WO2025084106A1 (ja) | 経鼻投与による細胞性免疫の誘導方法 | |
| Barnard et al. | Intranasal protollin formulated recombinant SARS-CoV S protein elicits respiratory and serum neutralizing antibodies | |
| Julander et al. | Antiviral Activity of (−)-Carbocyclic Cytosine [(−)-Carbodine] Against Venezuelan Equine Encephalitis Virus (VEEV) in a Mouse Model | |
| JP2016132636A (ja) | 人以外の陸上動物用のウイルス感染症に対する抗体誘導剤とその補助剤 | |
| HK1004060B (en) | Oral vaccine comprising antigen surface-associated with red blood cells | |
| WO2015027056A1 (en) | NOVEL METHOD OF REDUCING ANTIGENIC DRIFT OR REASSORTMENT OF VIRUSES IN A HOST ANIMAL USING α- INTERFERON |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091207 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091224 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100104 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120217 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120516 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120523 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120801 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120926 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130128 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130311 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20130510 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140422 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140425 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140522 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140528 |